WELIREG (belzutifan) Patient Assistance Program
Don’t let the high cost of brand specialty HIF-2α inhibitor therapy disrupt your treatment. We help eligible patients access Welireg (belzutifan) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Welireg (belzutifan) is FDA-approved for adults with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma, central nervous system hemangioblastoma, or pancreatic neuroendocrine tumors not requiring immediate surgery, and for advanced renal cell carcinoma following PD-1/PD-L1 inhibitor and VEGFR-targeted therapy. It is a first-in-class oral HIF-2α (hypoxia-inducible factor 2 alpha) inhibitor.
- Without assistance, Welireg costs commonly run approximately $30,000–$35,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Welireg for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Welireg in the U.S. as of 2026. For advanced RCC following PD-1 and VEGFR inhibitors, alternatives include cabozantinib (Cabometyx), lenvatinib + everolimus, axitinib (generic available), and tivozanib (Fotivda). For VHL-associated tumors, Welireg has a unique mechanism of action.
What Is Welireg Prescription Assistance Program?
The Welireg Prescription Assistance Program is a manufacturer-sponsored initiative that provides Welireg at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for VHL-associated tumor patients and advanced RCC patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Welireg costs roughly $30,000–$35,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$34,000 | Save substantially |
| CVS Pharmacy | ~$35,000 | Save substantially |
| Walmart | ~$31,000 | Save substantially |
| Costco | ~$30,500 | Save substantially |
Specialty Pharmacy | ~$32,000 | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Welireg Prescription Program?
The Patient Assistance Program is free to apply for and provides Welireg at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Welireg:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $30,000–$35,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Welireg assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Welireg Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Welireg:
Welireg (belzutifan) is a first-in-class oral selective inhibitor of HIF-2α (hypoxia-inducible factor 2 alpha) used for tumors driven by HIF-2α dysregulation. It is particularly effective in von Hippel-Lindau (VHL) disease-associated tumors, where loss of VHL protein leads to HIF-2α accumulation.
How Welireg Works:
Belzutifan works as a small-molecule inhibitor that binds to HIF-2α, a transcription factor that abnormally accumulates in VHL disease and sporadic clear cell RCC to drive tumor growth. By preventing HIF-2α from dimerizing with HIF-1β, the drug successfully blocks the transcription of genes involved in angiogenesis, cell proliferation, and cell survival. This targeted action results in tumor regression or stabilization for VHL-associated tumors and provides clinical benefit in advanced clear cell RCC. Ultimately, it serves as the first FDA-approved targeted therapy for VHL disease, helping many patients delay or completely avoid surgical interventions.
Form and use:
Marketed under the brand name Welireg, this medication is taken orally once daily at a standard dose of 120 mg, which consists of three 40 mg tablets. It can be administered either with or without food, but it should be taken at approximately the same time every day. Patients need to be cautious with concurrent medications, as strong UGT2B17 or CYP2C19 inhibitors and inducers can significantly alter the drug’s levels in the body.
Generic availability:
As of 2026, there is no generic version of Welireg available in the United States. For patients with advanced clear cell RCC who have already progressed on PD-1/PD-L1 and VEGFR-targeted therapies, alternative choices include cabozantinib, lenvatinib plus everolimus, axitinib, tivozanib, or a re-challenge with prior immunotherapy. For VHL disease specifically, Welireg is the very first targeted therapy option, whereas historical alternatives were limited to surgery, ablation, and supportive care.
Warnings:
Welireg carries a Boxed Warning for severe anemia and hypoxia, which requires hemoglobin monitoring at baseline and throughout therapy, sometimes necessitating transfusions or erythropoiesis-stimulating agents. Hypoxia can occur independently of anemia, meaning patients’ oxygen saturation (SpO2) must also be closely monitored and treated as clinically indicated. Additionally, the drug comes with warnings regarding embryo-fetal toxicity and a reduced efficacy of hormonal contraceptives. Significant drug interactions exist, meaning the concurrent use of strong UGT2B17 and CYP2C19 inhibitors should be strictly avoided.
FAQ (Frequently Asked Questions)
How Much Does Welireg Cost Without Insurance?
Welireg costs approximately $30,000–$35,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Welireg at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
What Is HIF-2α And Why Block It?
HIF-2α (hypoxia-inducible factor 2 alpha) is a transcription factor that turns on genes for angiogenesis, glucose metabolism, and cell growth. In von Hippel-Lindau (VHL) disease, loss of the VHL protein causes HIF-2α to accumulate abnormally — driving the development of multiple tumor types (kidney cancer, hemangioblastomas of the brain/spine, pancreatic neuroendocrine tumors). Many sporadic clear cell renal cell carcinomas also have HIF-2α-driven biology. Welireg blocks HIF-2α activity and shrinks or stabilizes these tumors.
How Will Welireg Help My VHL Disease?
In VHL patients, Welireg has produced meaningful tumor responses across multiple VHL-associated tumor types — RCC, hemangioblastomas, and pancreatic NETs — allowing some patients to delay or avoid surgical interventions. Many patients with VHL have multiple tumors that grow over time; before Welireg, the main treatment was repeated surgery as tumors became dangerous. Welireg provides a systemic option that can shrink or stabilize multiple tumors simultaneously.
Why Does Welireg Cause Anemia?
Welireg blocks HIF-2α, which normally drives erythropoietin (EPO) production — the hormone that stimulates red cell production. By blocking HIF-2α, Welireg reduces EPO and causes anemia in most patients. Hgb monitoring is required; some patients need erythropoiesis-stimulating agents (EPO injections) or transfusion. This anemia is ‘on-target’ — it reflects the drug working — and is managed rather than prevented.
Are There Drug Interactions I Should Know About?
Yes. Belzutifan is metabolized by UGT2B17 and CYP2C19. Strong inhibitors raise levels; inducers reduce levels. Welireg also reduces the effectiveness of hormonal contraceptives — use non-hormonal or barrier contraception. Tell every prescriber and pharmacist about Welireg.
Can I Get Welireg Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — for advanced RCC, switching to cabozantinib, lenvatinib + everolimus, generic axitinib, or tivozanib (each with its own PAP); for VHL disease, traditional management with surveillance and surgery, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the VHL Alliance, Kidney Cancer Association, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Welireg, our team may be able to help you access assistance programs designed to make brand specialty HIF-2α inhibitor therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.